The present invention is a liquid pharmaceutical composition for use in medical treatment, wherein the liquid pharmaceutical composition comprises a non-conjugated 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone). Oral or intragastric administration of 10-250 mL of a liquid pharmaceutical composition, which is a monophasic aqueous solution, comprising at least 7% by weight of water and 0.2-9 mg / mL edaravone, wherein treatment results in 30-300 mg edaravone. Liquid pharmaceutical compositions, including administration. [Selection diagram] None本発明は、医療処置において使用するための液体状医薬組成物であって、前記液体状医薬組成物が、非複合体３－メチル－１－フェニル－２－ピラゾリン－５－オン（エダラボン）の一相性水溶液であり、少なくとも７重量％の水と０．２～９ｍｇ／ｍＬのエダラボンを含み、処置が３０～３００ｍｇのエダラボンをもたらすための１０～２５０ｍＬの液体状医薬組成物の経口又は胃内投与を含む、液体状医薬組成物に関する。【選択図】なし
